Antiparkinsonian drug doses and neuroleptic receptors.
The clinical potency of 3 drugs, apomorphine, N-propylnorapomorphine, and bromocryptine, have been found to be closely correlated to their potencies in competing for 3H-haloperidol and 3H-spiroperidol both of which label the dopamine receptor. This correlation indicates that the direct binding assay may be used to predict clinical potencies of anti-parkinsonian drugs, and indicates that agonists as well as antagonists compete potently for 3H-neuroleptic binding.
D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001058:Apomorphine / Q000008:administration & dosage / Q000031:analogs & derivatives; D001971:Bromocriptine / Q000008:administration & dosage; D002417:Cattle; D002421:Caudate Nucleus / Q000378:metabolism; D006220:Haloperidol / Q000378:metabolism; D066298:In Vitro Techniques; D011954:Receptors, Dopamine / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism; D014316:Tritium
D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D014316:Tritium; D001971:Bromocriptine; D013134:Spiperone; C009074:N-n-propylnorapomorphine; D006220:Haloperidol; D001058:Apomorphine